

**2023高雄國際癌症研討會 議程表**

**2023 Kaohsiung International Cancer Symposium**

主辦單位：  
台灣乳房醫學會、高雄醫學大學附設中和紀念醫院 乳房外科/癌症中心、社團法人高雄市乳癌防治衛教學會、高雄市醫事暨醫務行政學會 Organizers：  
Taiwan Breast Cancer Society、Kaohsiung Medical University Chung-Ho Memorial Hospital Division of Breast Surgery / Cancer Center、Kaohsiung Breast Cancer Prevention and Education Society、Kaohsiung College of Healthcare Professionals and Executives  
研討會日期：2023 年 4 月22 日(六) - 2023 年4月 23 日(日) Date: April 22 -23, 2023

研討會地點：高雄醫學大學附設中和紀念醫院啟川大樓六樓 第一講堂

Venue: Auditorium I, 6F Building E, Kaohsiung Medical University Chung-Ho Memorial Hospital

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **4月22 日(星期六) Saturday, 22 April** | | | | |
| **Time** | **Topic** | **Speaker** | | **Moderator** |
| **07:45-08:00** | 貴賓致詞 | | | |
| **08:00-08:30** | Marker-guided effective therapy (Mget) | Mien-Chie Hung  洪明奇 | Ming-Feng Hou  侯明鋒 | |
| **08:30-09:00** | Innovating precision care plan for chemotherapy-induced cytopenia, neuropathy, and sarcopenia through the neuroprotective mechanisms | Meng-Ru Shen  沈孟儒 | Mien-Chie Hung 洪明奇 | |
| **09:00-09:30** | Proteogenomic Landscape of East-Asian Breast Cancer Reveals Pathogenesis and Subtypes for Prognostic and Therapeutic opportunities | Yu-Ju Chen 陳玉如 | Lu-Hai Wang  王陸海 | |
| **09:30-10:00** | Mitochondrial Metabolism in Breast Cancer | Shyng-Shiou F. Yuan 袁行修 | King-Jen Chang  張金堅 | |
| **10:00-10:20** | **Coffee Break** | | | |
| **10:20-10:50** | Efficacy and Safety data of Sacituzumab govitecan in mTNBC and its Real-World Cases | Hui-Ti See | Shou-Tung Chen 陳守棟 | |
| **10:50-11:20** | An Optimized Treatment in High-risk HER2 negative early Breast Cancer | Chieh-Ni Kao 高捷妮 | Chiun-Sheng Huang  黃俊升 | |
| **11:20-11:50** | Revision of adjuvant anthracycline chemotherapy in early breast cancer | Guo-Shiou Liao  廖國秀 | Jyh-Cherng Yu  俞志誠 | |
| **11:50-12:20** | Identifying unmet needs for improving care for patients with chemotherapy-induced neutropenia | Jun-Ping Shiau 蕭君平 | Guo-Shiou Liao  廖國秀 | |
| **12:20-13:30** | **Lunch** | | | |
| **13:30-14:00** | Bone Health Management and SRE Prevention in Breast Cancer Patients: Experiences from NCKUH | Shuen-Ru Yang  楊舜如 | Shin-Cheh Chen  陳訓徹 | |
| **14:00-14:30** | Reducing the risk of recurrence in HR+, HER2- early breast cancer | Wen-Ling Kuo 郭玟伶 | Shyr-Ming Sheen-Chen  沈陳石銘 | |



|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Time** | **Topic** | **Speaker** | **Moderator** | |
| **14:30-15:00** | The maximization strategy from neoadjuvant to adjuvant in HER2 breast cancer | Liang-Chih Liu 劉良智 | Ta-Chung Chao  趙大中 | |
| **15:00-15:30** | Striving for the optimal treatment outcome for the broadest set of patients in HR+HER2-mBC with CDK4/6i | Huang-Po Hsiang  黃柏翔 | Ling-Ming Tseng  曾令民 | |
| **15:30-15:50** | **Coffee Break** | | | |
| **15:50-16:20** | Fix Dose Combination for HER2 Dual Blockade: Deep Dive into Asian Experience | Huang Liang  黃亮 | | Yao-Lung Kuo  郭耀隆 |
| **16:20-16:50** | CDK4/6i in HR+HER2-mBC pre-menopausal patient update | Yu-Hsuan Kuo 郭雨萱 | | Liang-Chih Liu 劉良智 |
| **16:50-17:20** | Give HER 1 More Chance  ENHERTU as a New SOC in HER2 low | Chieh-Han Chuang  莊捷翰 | | Ming-Yang Wang  王明暘 |
| **17:20-17:50** | The benefit of extended adjuvant therapy for HER2 Breast cancer | Hung-Wen Lai 賴鴻文 | | Dar-Ren Chen 陳達人 |
| **17:50-18:00** | **Panel Discussion & Closing** | | | |



|  |  |  |  |
| --- | --- | --- | --- |
| **4 月 23 日(星期日) Sunday, 23 April** | | | |
| **Breast Cancer** | | | |
| **Time** | **Topic** | **Speaker** | **Moderator** |
| **08:00-08:30** | Improved systemic therapy for breast cancer | Shinji Ohno  大野真司 | Chao-Ming Hung  洪朝明  Ching-Kuen Pan 潘慶坤 |
| **08:30-09:00** | Differences between East and West on breast cancer treatment | Takashi Ishikawa  石川孝 | Chen-Hsiang Chang  張振祥  Kuo-Ting Lee 李國鼎 |
| **09:00-09:30** | Update on the establishment of a deep learning system for breast ultrasound diagnosis for clinical application | Tetsu Hayashida  林田哲 | Kun-Ming Rau 饒坤銘  Yi-Chia Wu 吳益嘉 |
| **09:30-10:00** | Combination treatment of Eribulin with Immulogy agent in TNBC treatment | Tomoharu Sugie  杉江知治 | Wen-Hung Kuo  郭文宏 |
| **10:00-10:20** | **Coffee Break** | | |
| **10:20-10:50** | Curability or irAE? Pros and Cons of ICI in peri-operative setting for TNBC | Ming-Shen Dai 戴明燊 | Fu Ou-Yang  歐陽賦 |
| **10:50-11:20** | Efficacy and safety of nanoparticle-albumin-bound paclitaxel mono-chemotherapy for metastatic breast cancer | Hung-Wen Lai 賴鴻文 | Chih-Jen Huang 黃志仁 |
| **11:20-11:50** | Expanding the benefits of PARP inhibitors to more patients with advanced breast cancer | Wai-Shan Chung  鍾煒珊 | Shen-Liang Shih 施昇良 |
| **11:50-12:20** | New era of endocrien therapy in advanced breast cancer | An-Chieh Feng  馮安捷 | Fang-Ming Chen 陳芳銘 |
| **12:20-12:30** | **Closing** | Fang-Ming Chen 陳芳銘 | |